Pharmacokinetics and Safety Profile of Tigecycline in Children Aged 8 to 11 Years With Selected Serious Infections: A Multicenter, Open-Label, Ascending-Dose Study

Clinical Therapeutics

Volumn 34, Issue 2, 2012, Pages

  Purdy, Jay ^a   Jouve, Sylvie ^a   Yan, Jean Li ^a   Balter, Ivana ^a   Dartois, Nathalie ^a   Cooper, C Angel ^a   Korth Bradley, Joan ^a  

^a PFIZER INC   (United States)

Author keywords

Pediatrics; Pharmacokinetics; Tigecycline

Indexed keywords

TIGECYCLINE;

ABDOMINAL INFECTION; ABDOMINAL PAIN; AMYLASE BLOOD LEVEL; ANUS FISTULA; ARTICLE; BACTERIAL INFECTION; CHILD; CLINICAL ASSESSMENT; COMMUNITY ACQUIRED PNEUMONIA; DESCRIPTIVE RESEARCH; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; NAUSEA; PEDIATRICS; PHARMACODYNAMICS; PHASE 2 CLINICAL TRIAL; SCHOOL CHILD; SIDE EFFECT; SKIN INFECTION; SKIN STRUCTURE INFECTION; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; WOUND INFECTION;

EID: 84856754658     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2011.12.010     Document Type: Article

References (22)

1. Petersen P.J., Jacobus N.V., Weiss W.J., et al. In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936). Antimicrob Agents Chemother 1999, 43:738-744.
2. Chopra I. New developments in tetracycline antibiotics: glycylcyclines and tetracycline efflux pump inhibitors. Drug Resist Update 2002, 5:119-125.
3. Schnappinger D., Hillen W. Tetracyclines: antibiotic action, uptake, and resistance mechanisms. Arch Microbiol 1996, 165:359-369.
4. Babinchak T., Ellis-Grosse E., Dartois N., et al. The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data. Clin Infect Dis 2005, 41(Suppl 5):S354-S367.
5. Bouchillon S.K., Hoban D.J., Johnson B.M., et al. In vitro activity of tigecycline against 3989 gram-negative and gram-positive clinical isolates from the United States Tigecycline Evaluation and Surveillance Trial (TEST Program; 2004). Diagn Microbiol Infect Dis 2005, 52:173-179.
6. Ellis-Grosse E.J., Babinchak T., Dartois N., et al. The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam. Clin Infect Dis 2005, 41(Suppl 5):S341-S353.
7. Oliva M.E., Rekha A., Yellin A., et al. A multicenter trial of the efficacy and safety of tigecycline versus imipenem/cilastatin in patients with complicated intra-abdominal infections. BMC Infect Dis 2005, 5:88. [Study ID Numbers: 3074A1-301-WW; ClinicalTrials.gov Identifier: NCT00081744].
8. Sacchidanand S., Penn R.L., Embil J.M., et al. Efficacy and safety of tigecycline monotherapy compared with vancomycin plus aztreonam in patients with complicated skin and skin structure infections: Results from a phase 3, randomized, double-blind trial. Int J Infect Dis 2005, 9:251-261.
9. Tanaseanu C., Bergallo C., Teglia O., et al. Integrated results of 2 phase 3 studies comparing tigecycline and levofloxacin in community-acquired pneumonia. Diagn Microbiol Infect Dis 2008, 61:329-338.
10. Muralidharan G., Micalizzi M., Speth J., et al. Pharmacokinetics of tigecycline after single and multiple doses in healthy subjects. Antimicrob Agents Chemother 2005, 49:220-229.
11. Van Wart S.A., Owen J.S., Ludwig E.A., et al. Population pharmacokinetics of tigecycline in patients with complicated intra-abdominal or skin and skin structure infections. Antimicrob Agents Chemother 2006, 50:3701-3707.
12. Andes D., van Ogtrop M. In vivo characterization of the pharmacodynamics of flucytosine in a neutropenic murine disseminated candidiasis model. Antimicrob Agents Chemother 2000, 44:938-942.
13. Meagher A.K., Passarell J.A., Cirincione B.B., et al. Exposure-response analyses of tigecycline efficacy in patients with complicated skin and skin-structure infections. Antimicrob Agents Chemother 2007, 51:1939-1945.
14. Passarell J.A., Meagher A.K., Liolios K., et al. Exposure-response analyses of tigecycline efficacy in patients with complicated intra-abdominal infections. Antimicrob Agents Chemother 2008, 52:204-210.
15. van Ogtrop M.L., Andes D., Stamstad T.J., et al. In vivo pharmacodynamic activities of two glycylcyclines (GAR-936 and WAY 152,288) against various gram-positive and gram-negative bacteria. Antimicrob Agents Chemother 2000, 44:943-949.
16. Maples H., James L., Stowe C. Special pharmacokinetic and pharmacodynamic considerations in children. Applied Pharmacokinetics and Pharmacodynamics: Principles of Therapeutic Drug Monitoring 2006, 213-230. Lippincott, Williams, and Wilkins, Philadelphia. 4th ed. M.E. Burton, L.M. Shaw, J.J. Schentag, W.E. Evans (Eds.).
17. Korth-Bradley J.M., Troy S.M., Matschke K., et al. Tigecycline Pharmacokinetics in Subjects With Various Degrees of Renal Function. J Clin Pharmacol 2011, 2011 Sep 27. [Epub ahead of print].
18. Jusko W. Guidelines for collection and analysis of pharmacokinetic data. Applied Pharmacokinetics & Pharmacodynamics: Principles of Therapeutic Drug Monitoring 2006, 8-29. Philadelphia, Lippincott Williams & Wilkins. 4th ed. M.E. Burton, L.M. Shaw, J.J. Schentag, W.E. Evans (Eds.).
19. Clopper C., Pearson E.S. The use of confidence or fiducial limits illustrated in the case of the binomial. Biometrika 1934, 26:404-413.
20. Bouchillon S.K., Hoban D.J., Johnson B.M., et al. In vitro evaluation of tigecycline and comparative agents in 3049 clinical isolates: 2001 to 2002. Diagn Microbiol Infect Dis 2005, 51:291-295.
21. Rubino C., Bhavnani S., Forrest A., et al. Pharmacokinetic-Pharmacodynamic (PK-PD) Analysis for Efficacy (EFF) of Tigecycline (TIG) in Patients with Hospital- (HAP) or Community-Acquired Pneumonia (CAP) Presentation at ICAAC 2007, Abstract A-588.
22. Ambrose P.G., Meagher A.K., Passarell J.A., et al. Use of a clinically derived exposure-response relationship to evaluate potential tigecycline-Enterobacteriaceae susceptibility breakpoints. Diagn Microbiol Infect Dis 2009, 63:38-42.